Results 101 to 110 of about 8,556,350 (292)

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Ethnic Studies Newsletter Vol. 4 No. 2

open access: yes, 1983
Seven page newsletter from the Ethnic Studies department dated December 1983. Newsletter is Volume 4, Number 2. Newsletter includes pieces on Dr. Benjamin P.
Ethnic Studies Department;
core   +1 more source

ОЙРАТЫ ЗАПАДНОЙ МОНГОЛИИ И СЕВЕРО-ЗАПАДНОГО КИТАЯ: ВОПРОСЫ ЭТНИЧЕСКОЙ ИСТОРИИ, ДЕМОГРАФИИ И ГЕОГРАФИИ РАССЕЛЕНИЯ ВО ВТОРОЙ ПОЛОВИНЕ XVIII ВЕКА

open access: yesOriental Studies, 2018
The author of this article gives the review of ethnic history of Oyrats of the western Mongolia and northwest China in second half of the XVIII century.
Utash Borisovich Ochirov
doaj  

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

open access: yesMolecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu   +3 more
wiley   +1 more source

On the methodology of palaeohistorical reconstructions

open access: yesПоволжская археология, 2015
Investigations into the pre-written history embracing more than 95% of the history of mankind (prehistory / palaeohistory) differs in terms of its sources and methods from the history taken in its narrow meaning, relying principally on the written ...
Vladimir V. Napolskikh
doaj  

CEACAM1 participation in breast cancer progression

open access: yesMolecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin   +3 more
wiley   +1 more source

Ethnic Studies Newsletter Vol. 6 No. 2

open access: yes, 1986
Seven page newsletter from the Ethnic Studies department dated Spring 1986. Newsletter is Volume 6, Number 2. Newsletter includes Feature on Bill Flores; Calendar of Events; Faculty Accomplishments; and list of Ethnic Studies Faculty and ...
Ethnic Studies Department;
core   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

open access: yesMolecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas   +16 more
wiley   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

open access: yesMolecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla   +4 more
wiley   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

open access: yesMolecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy